Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Period	Debt/Equity
2015-12-31	-2.87
2016-12-31	-2.80
2017-12-31	-42.34
2018-12-31	-1.96
2019-12-31	-2.26
2020-12-31	-2.50
2021-12-31	16.63
2022-12-31	5.90
2023-12-31	-16.14
2024-12-31	-2.52

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OMER	$11.91	+3.48%	1.28M
3
4
5

Omeros Corporation (OMER) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Omeros Corporation Data in Excel

More OMER Financial Data